Want to join the conversation?
Healthcare company $JNJ said Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) for daratumumab to the US FDA. The application seeks to expand the current indication, using daratumumab in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.